Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 153

1.

Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC.

Leuk Lymphoma. 2012 Jan;53(1):123-9. doi: 10.3109/10428194.2011.597905. Epub 2011 Aug 1.

PMID:
21806350
[PubMed - indexed for MEDLINE]
2.

Enhanced histone deacetylase enzyme activity in primary myelofibrosis.

Wang JC, Chen C, Dumlao T, Naik S, Chang T, Xiao YY, Sominsky I, Burton J.

Leuk Lymphoma. 2008 Dec;49(12):2321-7. doi: 10.1080/10428190802527699.

PMID:
19052980
[PubMed - indexed for MEDLINE]
3.

Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC.

Eur J Haematol. 2011 Jul;87(1):54-60. doi: 10.1111/j.1600-0609.2011.01618.x.

PMID:
21447007
[PubMed - indexed for MEDLINE]
4.

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.

Larsen TS, Pallisgaard N, Møller MB, Hasselbalch HC.

Eur J Haematol. 2007 Dec;79(6):508-15. Epub 2007 Oct 23.

PMID:
17961178
[PubMed - indexed for MEDLINE]
5.

Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations.

Boveri E, Passamonti F, Rumi E, Pietra D, Elena C, Arcaini L, Pascutto C, Castello A, Cazzola M, Magrini U, Lazzarino M.

Br J Haematol. 2008 Jan;140(2):162-8. Epub 2007 Nov 19.

PMID:
18028479
[PubMed - indexed for MEDLINE]
6.

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis.

Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto EX, Zanichelli MA, Simões BP, de Souza AM, Castro FA.

J Hematol Oncol. 2012 Feb 2;5:2. doi: 10.1186/1756-8722-5-2.

PMID:
22300941
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].

Schwarz J, Penka M, Campr V, Pospísilová D, Kren L, Nováková L, Bodzásová C, Brychtová Y, Cerná O, Dulícek P, Joniásová A, Kissová J, Korístek Z, Schützová M, Vonke I, Walterová L.

Vnitr Lek. 2011 Feb;57(2):189-213. Review. Czech.

PMID:
21416861
[PubMed - indexed for MEDLINE]
8.

[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].

Iványi JL, Marton E, Plander M.

Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226. Hungarian.

PMID:
22011365
[PubMed - indexed for MEDLINE]
9.

Gene expression profiling with principal component analysis depicts the biological continuum from essential thrombocythemia over polycythemia vera to myelofibrosis.

Skov V, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC, Larsen TS.

Exp Hematol. 2012 Sep;40(9):771-780.e19. doi: 10.1016/j.exphem.2012.05.011. Epub 2012 Jun 1.

PMID:
22659388
[PubMed - indexed for MEDLINE]
10.

Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.

Michiels JJ, Kutti J, Stark P, Bazzan M, Gugliotta L, Marchioli R, Griesshammer M, van Genderen PJ, Brière J, Kiladjian JJ, Barbui T, Finazzi G, Berlin NI, Pearson TC, Green AC, Fruchtmann SM, Silver RT, Hansmann E, Wehmeier A, Lengfelder E, Landolfi R, Kvasnicka HM, Hasselbalch H, Cervantes F, Thiele J, et al.

Neth J Med. 1999 Feb;54(2):46-62. Review.

PMID:
10079679
[PubMed - indexed for MEDLINE]
11.

Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).

Michiels JJ, Bernema Z, Van Bockstaele D, De Raeve H, Schroyens W.

Pathol Biol (Paris). 2007 Mar;55(2):92-104. Epub 2006 Aug 21. Review.

PMID:
16919893
[PubMed - indexed for MEDLINE]
12.

The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.

Risum M, Madelung A, Bondo H, Bzorek M, Kristensen MH, Stamp IM, Hasselbalch HC.

APMIS. 2011 Aug;119(8):498-504. doi: 10.1111/j.1600-0463.2011.02754.x. Epub 2011 Apr 17.

PMID:
21749449
[PubMed - indexed for MEDLINE]
13.

Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray.

Kawamata N, Ogawa S, Yamamoto G, Lehmann S, Levine RL, Pikman Y, Nannya Y, Sanada M, Miller CW, Gilliland DG, Koeffler HP.

Exp Hematol. 2008 Nov;36(11):1471-9. doi: 10.1016/j.exphem.2008.06.006. Epub 2008 Aug 23.

PMID:
18723266
[PubMed - indexed for MEDLINE]
14.

Molecular profiling of peripheral blood cells from patients with polycythemia vera and related neoplasms: identification of deregulated genes of significance for inflammation and immune surveillance.

Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, Kruse TA, Hasselbalch HC.

Leuk Res. 2012 Nov;36(11):1387-92. doi: 10.1016/j.leukres.2012.07.009. Epub 2012 Aug 9.

PMID:
22877729
[PubMed - indexed for MEDLINE]
15.

[Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].

Brière J.

Bull Acad Natl Med. 2007 Mar;191(3):535-48. Review. French.

PMID:
18072652
[PubMed - indexed for MEDLINE]
16.

The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study.

Rudzki Z, Sacha T, Stój A, Czekalska S, Wójcik M, Skotnicki AB, Grabowska B, Zduńczyk A, Okoń K, Stachura J.

Int J Hematol. 2007 Aug;86(2):130-6.

PMID:
17875526
[PubMed - indexed for MEDLINE]
17.

[Myeloproliferative diseases caused by JAK2 mutation].

Nagata K, Shimoda K.

Rinsho Byori. 2009 Apr;57(4):357-64. Review. Japanese.

PMID:
19489438
[PubMed - indexed for MEDLINE]
18.

[Research progress on molecular pathogenesis of myeloproliferative neoplasms].

Liu L, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Feb;19(1):239-43. Review. Chinese.

PMID:
21362261
[PubMed - indexed for MEDLINE]
19.

Dkk3 levels in patients with myeloproliferative neoplasms.

Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.

Thromb Res. 2014 Feb;133(2):218-21. doi: 10.1016/j.thromres.2013.11.003. Epub 2013 Nov 14.

PMID:
24309205
[PubMed - indexed for MEDLINE]
20.

Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.

Ann Hematol. 2007 Apr;86(4):245-53. Epub 2007 Jan 30.

PMID:
17262192
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk